Literature DB >> 27068530

Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human Cancers.

Deilson Elgui de Oliveira1, Bárbara G Müller-Coan2, Joseph S Pagano3.   

Abstract

Cancer progression begins when malignant cells colonize adjacent sites, and it is characterized by increasing tumor heterogeneity, invasion and dissemination of cancer cells. Clinically, progression is the most relevant stage in the natural history of cancers. A given virus is usually regarded as oncogenic because of its ability to induce malignant transformation of cells. Nonetheless, oncogenic viruses may also be important for the progression of infection-associated cancers. Recently this hypothesis has been addressed because of studies on the contribution of the Epstein-Barr virus (EBV) to the aggressiveness of nasopharyngeal carcinoma (NPC). Several EBV products modulate cancer progression phenomena, such as the epithelial-mesenchymal transition, cell motility, invasiveness, angiogenesis, and metastasis. In this regard, there are compelling data about the effects of EBV latent membrane proteins (LMPs) and EBV nuclear antigens (EBNAs), as well as nontranslated viral RNAs, such as the EBV-encoded small nonpolyadenylated RNAs (EBERs) and viral microRNAs, notably EBV miR-BARTs. The available data on the mechanisms and players involved in the contribution of EBV infection to the aggressiveness of NPC are discussed in this review. Overall, this conceptual framework may be valuable for the understanding of the contribution of some infectious agents in the progression of cancers.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epstein–Barr virus; cancer progression; malignant invasion; metastasis; nasopharyngeal carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27068530      PMCID: PMC5489061          DOI: 10.1016/j.tim.2016.03.008

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  89 in total

Review 1.  EBV the prototypical human tumor virus--just how bad is it?

Authors:  David A Thorley-Lawson
Journal:  J Allergy Clin Immunol       Date:  2005-08       Impact factor: 10.793

Review 2.  Applying what we know to accelerate cancer prevention.

Authors:  Graham A Colditz; Kathleen Y Wolin; Sarah Gehlert
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

3.  Prevalence and prognostic significance of Epstein-Barr virus infection in classical Hodgkin's lymphoma: a meta-analysis.

Authors:  Ju-Han Lee; Younghye Kim; Jung-Woo Choi; Young-Sik Kim
Journal:  Arch Med Res       Date:  2014-06-14       Impact factor: 2.235

Review 4.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis.

Authors:  Catherine de Martel; Jacques Ferlay; Silvia Franceschi; Jérôme Vignat; Freddie Bray; David Forman; Martyn Plummer
Journal:  Lancet Oncol       Date:  2012-05-09       Impact factor: 41.316

5.  NF-κB-mediated transcriptional upregulation of TNFAIP2 by the Epstein-Barr virus oncoprotein, LMP1, promotes cell motility in nasopharyngeal carcinoma.

Authors:  C-C Chen; H-P Liu; M Chao; Y Liang; N-M Tsang; H-Y Huang; C-C Wu; Y-S Chang
Journal:  Oncogene       Date:  2013-08-26       Impact factor: 9.867

6.  Epstein-Barr virus latent membrane protein 1 promotes concentration in multivesicular bodies of fibroblast growth factor 2 and its release through exosomes.

Authors:  Simona Ceccarelli; Vincenzo Visco; Salvatore Raffa; Naohiro Wakisaka; Joseph S Pagano; Maria Rosaria Torrisi
Journal:  Int J Cancer       Date:  2007-10-01       Impact factor: 7.396

7.  Tyrosylprotein sulfotransferase-1 and tyrosine sulfation of chemokine receptor 4 are induced by Epstein-Barr virus encoded latent membrane protein 1 and associated with the metastatic potential of human nasopharyngeal carcinoma.

Authors:  Juan Xu; Xiyun Deng; Min Tang; Lili Li; Lanbo Xiao; Lifang Yang; Juanfang Zhong; Ann M Bode; Zigang Dong; Yongguang Tao; Ya Cao
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

8.  Upregulation of endocan by Epstein-Barr virus latent membrane protein 1 and its clinical significance in nasopharyngeal carcinoma.

Authors:  Ping-Hung Yu; Shu-Fan Chou; Chi-Long Chen; Hung Hung; Ching-Yu Lai; Pei-Ming Yang; Yung-Ming Jeng; Shwu-Fang Liaw; Huan-Hsien Kuo; Hey-Chi Hsu; Jen-Yang Chen; Won-Bo Wang
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

9.  The Epstein-Barr virus-encoded microRNA MiR-BART9 promotes tumor metastasis by targeting E-cadherin in nasopharyngeal carcinoma.

Authors:  Chung-Yuan Hsu; Yung-Hsiang Yi; Kai-Ping Chang; Yu-Sun Chang; Shu-Jen Chen; Hua-Chien Chen
Journal:  PLoS Pathog       Date:  2014-02-27       Impact factor: 6.823

10.  Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes.

Authors:  M Aga; G L Bentz; S Raffa; M R Torrisi; S Kondo; N Wakisaka; T Yoshizaki; J S Pagano; J Shackelford
Journal:  Oncogene       Date:  2014-03-24       Impact factor: 9.867

View more
  41 in total

1.  Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.

Authors:  Umama Z Siddiqi; Anup S Vaidya; Xinliu Li; Edyta Marcon; Sai Wah Tsao; Jack Greenblatt; Lori Frappier
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

2.  Incidence of Epstein-Barr Virus Among Women With Breast Cancer Using Monoclonal Antibodies for Latent Membrane Protein 1 (LMP1).

Authors:  Magdi M Salih; Amjed A Higgo; Amany S Khalifa; Emad M Eed
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

3.  Co-Incidence of Epstein-Barr Virus and High-Risk Human Papillomaviruses in Cervical Cancer of Syrian Women.

Authors:  Hamda Al-Thawadi; Lina Ghabreau; Tahar Aboulkassim; Amber Yasmeen; Semir Vranic; Gerald Batist; Ala-Eddin Al Moustafa
Journal:  Front Oncol       Date:  2018-07-02       Impact factor: 6.244

4.  Spectrum of Posttransplant Lymphoproliferations in NSG Mice and Their Association With EBV Infection After Engraftment of Pediatric Solid Tumors.

Authors:  Heather Tillman; Peter Vogel; Tiffani Rogers; Walter Akers; Jerold E Rehg
Journal:  Vet Pathol       Date:  2020-03-23       Impact factor: 2.221

5.  Incidence OF HPV and EBV in oral cancer and their clinico-pathological correlation- a pilot study of 108 cases.

Authors:  Shahi Vanshika; Agarwal Preeti; Qayoom Sumaira; Kumar Vijay; Tewari Shikha; Raghuvanshi Shivanjali; Singh Uma Shankar; Goel Madhu Mati
Journal:  J Oral Biol Craniofac Res       Date:  2021-01-23

6.  Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?

Authors:  Paola Cavalcante; Stefania Marcuzzo; Sara Franzi; Barbara Galbardi; Lorenzo Maggi; Teresio Motta; Raffaella Ghislandi; Antonella Buzzi; Luisella Spinelli; Lorenzo Novellino; Fulvio Baggi; Carlo Antozzi; Fabio Conforti; Tommaso Martino De Pas; Massimo Barberis; Pia Bernasconi; Renato Mantegazza
Journal:  Oncotarget       Date:  2017-09-08

7.  Small molecule perturbation of the CAND1-Cullin1-ubiquitin cycle stabilizes p53 and triggers Epstein-Barr virus reactivation.

Authors:  Nadezhda Tikhmyanova; Steve Tutton; Kayla A Martin; Fang Lu; Andrew V Kossenkov; Nicholas Paparoidamis; Shannon Kenney; Joseph M Salvino; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2017-07-17       Impact factor: 6.823

Review 8.  Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders.

Authors:  Julie Morscio; Thomas Tousseyn
Journal:  World J Transplant       Date:  2016-09-24

Review 9.  The oncogenic role of Epstein-Barr virus-encoded microRNAs in Epstein-Barr virus-associated gastric carcinoma.

Authors:  Jinglin Zhang; Tingting Huang; Yuhang Zhou; Alfred S L Cheng; Jun Yu; Ka Fai To; Wei Kang
Journal:  J Cell Mol Med       Date:  2017-10-09       Impact factor: 5.310

10.  Human regulatory proteins associate with non-coding RNAs from the EBV IR1 region.

Authors:  V S Tompkins; D P Valverde; W N Moss
Journal:  BMC Res Notes       Date:  2018-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.